A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma by Weijing Sun, Nirmal Veeramachaneni, Raed Al‐Rajabi, Rashna Madan, Anup Kasi, Mazin Al‐Kasspooles, Joaquina Baranda, Anwaar Saeed, Milind A. Phadnis, Andrew K. Godwin, Mojtaba Olyaee, Natalie Streeter, Alykhan Nagji, Junqiang Dai, Stephen Williamson

Get full text